DB Wealth Management Group’s Pacific Biosciences PACB Stock Holding History

DB Wealth Management Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$4.93K	Buy	+503	New	+$4.11K	﹤0.01%	315

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

DB Wealth Management Group's PACB Position: Q4 2023 in Review

DB Wealth Management Group opened a new position in Pacific Biosciences (PACB) in Q4 2023: 503 shares worth $4.93K. The stake represents ﹤0.01% of the portfolio and ranks #315 among its holdings.

274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

DB Wealth Management Group held 503 shares of Pacific Biosciences worth $4.93K as of Q4 2023.
Pacific Biosciences was a new DB Wealth Management Group position in Q4 2023.
Pacific Biosciences made up ﹤0.01% of DB Wealth Management Group's portfolio in Q4 2023, its #315 holding.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on DB Wealth Management Group's 13F filing for Q4 2023, filed 9 Jan 2024.